Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Revenue from contract with customers (Details)

v3.10.0.1
Summary of Significant Accounting Policies - Revenue from contract with customers (Details) - GlaxoSmithKline Intellectual Property Development Ltd - Collaboration and License Agreement
£ in Millions
1 Months Ended 12 Months Ended 16 Months Ended 55 Months Ended
Sep. 30, 2018
USD ($)
Sep. 30, 2017
GBP (£)
Sep. 30, 2017
USD ($)
Jun. 30, 2014
USD ($)
Dec. 31, 2018
USD ($)
contract
Dec. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaboration and License Agreement              
Number of contracts with customers | contract         1    
Option Exercise Fee, received   £ 20 $ 26,600,000        
Upfront payment received       $ 42,123,000      
Option exercise fee received     $ 26,610,000        
Option exercise fee $ 13,175,000         $ 39,785,000  
Amount of development milestone achieved             $ 66,404,000
Estimate of variable consideration         $ 0